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High mobility group (HMG) proteins are the most abundant non-histone chromatin
associated proteins. HMG proteins bind to DNA and nucleosome and alter the structure
of chromatin locally and globally. Accessibility to DNA within chromatin is a central
factor that affects DNA-dependent nuclear processes, such as transcription, replication,
recombination, and repair. HMG proteins associate with different multi-protein complexes
to regulate these processes by mediating accessibility to DNA. HMG proteins can be
subdivided into three families: HMGA, HMGB, and HMGN. In this review, we will focus
on recent advances in understanding the function of HMGA family members, specifically
their role in gene transcription regulation during development and cancer.
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INTRODUCTION
Chromatin constitutes the physiological template for transcrip-
tion, thereby increasing the complexity of gene transcription
regulation. Nucleosomes are the structural and functional units
of chromatin. A nucleosome is built of DNA surrounding a
histone octamer, which consists of two H2A–H2B dimers and
one (H3–H4)2 tetramer. In addition to nucleosomes, chro-
matin consists of non-histone chromatin-associated proteins. It
is well known that chromatin mediated regulation of transcrip-
tion involves DNAmethylation and histonemodifications (Zhang
et al., 2005; Karlic et al., 2010; Ha et al., 2011; Gohlke et al.,
2013). However the precise biological function of non-histone
chromatin-associated proteins is not yet clear. High mobility
group (HMG) proteins are the most abundant non-histone
chromatin associated proteins. Based on their DNA binding
domains, the HMG proteins are subdivided into three families
(Figure 1A): HMGA (containing AT-hooks), HMGB (contain-
ing HMG-boxes) and HMGN (containing nucleosomal binding
domains) (Bustin, 2001; Catez and Hock, 2010). HMG pro-
teins can recognize structure rather than a particular nucleotide
sequence and are able to bind to specific structures in DNA or
chromatin in a sequence-independent fashion via their respec-
tive functional motifs (Reeves, 2001). HMG proteins do not
possess intrinsic transcriptional activity while having the abil-
ity to modulate transcription of their target genes by alter-
ing the chromatin structure at the promoter and/or enhancers
(Reeves, 2010). Thus, they are called architectural transcrip-
tion factors. In this review, we will focus on recent advances in
understanding the function of HMGA family members. HMGA
family is comprised of HMGA1a, HMGA1b, HMGA1c, and
HMGA2. They are expressed highly during embryonic develop-
ment and in transformed cells. They are encoded by two distinct
genes. The HMGA1 gene gives rise to three proteins (HMGA1a,
HMGA1b, and HMGA1c) by alternative splicing of a common
transcript. With the exception of HMGA1c, the HMGA pro-
teins contain three short basic repeats called AT-hook motif and
a C-terminal acidic tail (Figure 1B) (Sgarra et al., 2004; Fusco
and Fedele, 2007; Hammond and Sharpless, 2008; Pfannkuche
et al., 2009). The amino acid sequence of the AT-hook motif is
K/RXRGRP (X = glycine or proline) and is flanked on either
side by positively charged residues. These characteristics deter-
mine the binding preference of HMGAproteins to both theminor
groove of AT-rich DNA stretches (Cui and Leng, 2007; Winter
et al., 2011) and to nucleosomes in a cooperative manner (Li
et al., 2006). HMGA proteins, when free in solution, possess
very little, if any, secondary structure as shown by biophysical
techniques such as circular dichroism (CD) (Lehn et al., 1988)
and nuclear magnetic resonance (NMR) spectroscopy (Evans
et al., 1995). However, when bound to DNA or proteins specif-
ically, the AT-hooks undergo from a disordered to ordered con-
formational change and influence the conformation of bound
DNA substrates in different ways including bending, straighten-
ing, unwinding, and inducing looping in linear DNA molecules.
The function of the C-terminal acidic region is poorly under-
stood. However, there are speculations that C-terminal acidic
tail is involved in protein-protein interaction and recruitment
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FIGURE 1 | The HMG proteins superfamily and model for HMGA proteins
mediated transcription activation. (A) Genealogical tree of human HMG
proteins. HMG proteins are divided into three families depending on their
DNA binding domains: HMGA (containing AT-hooks), HMGB (containing
HMG-boxes) and HMGN (containing nucleosomal binding domains).
CLUSTALW software was used to build rooted genealogical tree with branch
length (UPGMA) of human HMG group family members. (B) Schematic
representation of human HMGA proteins. HMGA1a, HMGA1b, HMGA1c, and
HMGA2 proteins contain unique DNA binding domains (DB, blue boxes) with
a characteristic AT-hook motif and a C terminal acidic domain (pink boxes).
HMGA1a and HMGA1b proteins show high sequence similarity. HMGA1b
lacks eleven amino acids before the second DB when compared to HMGA1a
and 1c. The amino acid sequence of HMGA1c differs from the one from
HGMA1a and 1b starting from amino acid 65 (green box). GPS DOG 2.0
software was used to illustrate protein structure domains (Ren et al., 2009).
(C–G) A model for the putative mechanism of HMGA proteins as factors
promoting nucleosome mobility and accessibility to specific DNA sites for
transcription activation is depicted. (C) The nucleosome is built of 146 bp
DNA (red line) surrounding the histone octamer (yellow cylinder), which
consist of two H2A-H2B dimers and one (H3–H4)2 tetramer. The linker
histone H1 (purple oval) binds to linker DNA outside the histone octamer at
the position where the DNA enters and exits the nucleosome core particle.
(D) HMGA proteins (green oval) can compete and displace histone H1 from
the chromatin. HMGA binding to linker DNA in the chromatin and the
subsequent displacement of histone H1 leads to decompactness of the
chromatin. (E) The relaxed chromatin structure acts as an anchoring site for
the recruitment of chromatin remodeling complexes (CRC, gray). Binding of
this complex is enhanced by HMGA proteins and induces eviction of core
histones and/or mobilization of complete histone octamers. (F) The
chromatin remodeling events make sequence-specific sites on the DNA
accessible for transcription factor (TF, red pentagon and hexagon) binding. (G)
HMGA proteins might facilitate the formation of transcription factor
complexes binding to these sequence-specific sites. Later, RNA polymerase
II (Pol II, blue oval) is recruited for transcription initiation (black arrow).
of factors during regulation of gene transcription (Xu et al.,
2011).
HMGA family members show high sequence homology; the
only difference between HMGA1a and HMGA1b is an inter-
nal deletion of eleven amino acids before the second AT-
hook domain. Although the sequence similarity may suggest
that these two isoforms could be biologically interchangeable,
there are reports that show the opposite. For example, it was
shown that tetracycline-regulated induction of HMGA1b in the
human breast epithelial cell line MCF7 caused them to progress
much more rapidly to a metastatic and highly malignant phe-
notype than did induced overexpression of HMGA1a (Reeves
et al., 2001). The differences in their posttranslational modi-
fications may explain the different cellular processes they are
involved in. Also the different spacing of AT-hook domains
between the different HMGA proteins could have a role in
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their different target gene selection and/or binding affinity
(Cleynen and Van De Ven, 2008).
HMGA AND CHROMATIN
In the nucleus of eukaryotic cells, genomic DNA is highly orga-
nized and packed into chromatin. Chromatin serves as sub-
strate for all kinds of DNA dependent processes and represents
a strong barrier to sequence specific recognition sites on the
DNA. Thus, to overcome this DNA sequence accessibility bar-
rier, it is a prerequisite to open the higher order chromatin
structure so that transcription regulators can access to specific
DNA sequences and execute their function. Histone H1 binds to
linker DNA and increases the compactness of higher order chro-
matin (Figures 1C,D). HMGA proteins compete with histone H1
for binding to linker DNA thereby inducing a loosening of the
chromatin structure, which has been demonstrated by different
techniques including fluorescence recovery after photobleaching
(FRAP), nuclear fractionation analysis and micrococcal nuclease
digestion (MNase) assays (Zhao et al., 1993; Catez et al., 2004;
Kishi et al., 2012). However, the molecular mechanism under-
lying the replacement of histone H1 by HMGA proteins which
results in chromatin opening is not well understood. Several
post-translational modifications have been reported for histone
H1, such as phosphorylation, methylation, acetylation and poly-
ADP-ribosylation (PARylation) (Snijders et al., 2008). Similar to
the core histones, these post-translational modifications of the
linker histone H1 play a role in regulation of chromatin structure.
PARP-1 mediated PARylation of histone H1 leads to nucleosome-
specific exchange of histone H1 by HMGB proteins inducing
local changes of chromatin structure (Ju et al., 2006). In a sim-
ilar manner, histone H1 post-translational modifications could
facilitate replacement of histone H1 by HMGA proteins thereby
inducing chromatin decompaction. It is well known that the
globular domain of histone H1 interacts and binds with linker
DNA. Several motifs for kinases are located inside the globular
domain or flanking it. Phosphorylation of these sites modulate
the binding affinity of histone H1 to linker DNA (Contreras et al.,
2003) and might play a role during replacement of histone H1 by
HMGA proteins.
HistoneH1 eviction from the chromatin is not enough to facil-
itate the access of regulatory elements on target genes because
the DNA is still wrapped around the core histones hindering the
accessibility of transcription factors to their binding elements.
Hence, there is further need of either eviction or mobilization
of core histones (Figures 1E,F). Several chromatin remodelers
might be involved in these processes. For example, the FACT
complex has been reported to participate in H2A/H2B histone
eviction/deposition (Belotserkovskaya et al., 2003), whereas ASF1
is involved in H3/H4 histone eviction/deposition (Schwabish and
Struhl, 2006). HMGA proteins bind to both nucleosomes (Li
et al., 2006) and chromatin remodelers (Malini et al., 2011) sug-
gesting a role of these proteins in eviction and/or mobilization of
core histones during transcriptional regulation.
HMGA AND TRANSCRIPTION
In eukaryotes, two types of core promoters are used for initia-
tion of gene transcription: promoters that are enriched with the
di-nucleotide sequence CpG and promoters that are CpG poor
(Antequera, 2003; Ramirez-Carrozzi et al., 2009; Deaton and Bird,
2011). CpG poor core promoters usually contain a TATA box, ini-
tiator sequences (INR), a TFIIB recognition element (BRE) and
downstream promoter elements (DPE) (Butler and Kadonaga,
2002; Levine and Tjian, 2003). These promoters have specific
single transcription start sites (TSS). In addition, a strong stim-
ulation of RNA polymerase II (Pol II) dependent transcription
initiation has been reported for these promoters by the synergis-
tic interplay of the TATA box and INR core promoter elements.
Recently, HMGA1 was identified as one of the factors required for
the synergy between the TATA box and INR elements (Figure 1G)
(Xu et al., 2011). However, there is still need of further investiga-
tion to test the relevance of this finding as a general mechanism of
transcription initiation. Gene transcription can also be regulated
by the interplay of core promoter elements along with regula-
tory DNA elements, such as enhancers and silencers, which might
be located several kilo base pairs (kbp) upstream or downstream
of the promoter. In response to defined signals, specific proteins
bind to the enhancer and form a complex called enhanceosome
(Munshi et al., 1999; Yie et al., 1999; Panne et al., 2007; Panne,
2008). Looping of the DNA brings the enhaceosome and the core
promoter in close proximity resulting in enhanced gene transcrip-
tion. HMGA proteins are involved in enhanceosome formation
(Bouallaga et al., 2000, 2003). In addition, it has been reported
that HMGA proteins have the ability to bend DNA (Chen et al.,
2010). Thus, a model can be suggested in which HMGA proteins
participate not only in the formation of the enhanceosome but
also in DNA looping and chromatin rearrangements that occur
to bring enhanceosomes and core promoter in close proximity
so that a coordinated assembly of the transcription initiation
complex at core promoter can take place.
It has been reported that the C-terminal domain of HMGA
proteins (Figure 1B) is required for the interaction of HMGA1
with TFIID (Xu et al., 2011). This interaction seems to medi-
ate core promoter specific functions since a C-terminal deletion
mutant of HMGA1 fails to initiate transcription (Figure 1G).
In addition, this domain contains several conserved phospho-
rylation sites, for example SQ sites, which are substrates for
the kinases DNA-PK, ATM and ATR. These kinases have been
involved in different signal transduction pathways. In addition,
ATM and ATR interact with and phosphorylate HMGA group
proteins (Pentimalli et al., 2008; Palmieri et al., 2011; Natarajan
et al., 2013). It would be interesting to elucidate the biological
relevance of this finding within the context of different sig-
nal transduction pathways to understand the signaling events
responsible for fine-tuning the HMGAmediated cell specific gene
transcription.
The second type of promoters, which contain CpG islands,
lack TATA boxes and display multiple heterogeneous TSSs. These
promoters tend to be enriched with binding elements for SP1,
NRF-1, E2F, and ETS transcription factors (Landolin et al., 2010;
Deaton and Bird, 2011). It was shown that HMGA1 interacts with
SP1 and facilitates its binding to both the human insulin receptor
(INSR) gene promoter and the herpes simplex virus latency-active
promoter 2 (Figure 1G) (French et al., 1996; Foti et al., 2003).
This suggests that HMGA family members may be involved in
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the transcriptional activation of CpG rich promoters. Although
previous reports support the specific binding of HMGA to AT-
rich sequences on the DNA (Cleynen et al., 2007; Cui and Leng,
2007; Winter et al., 2011), it would be interesting to compare
transcriptome data after HMGA gain-of-function with whole-
genome chromatin immunoprecipitation sequencing (ChIP-seq)
data after HMGA-ChIP to find out whether HMGAmediated reg-
ulation of CpG rich promoter is a general mechanism or it is only
restricted to specific genes.
HMGA ROLE DURING DEVELOPMENT
HMGA proteins are present at high levels in various undiffer-
entiated tissues during embryonic development and their levels
are strongly reduced, or almost absent in case of HMGA2, in
the corresponding adult tissues (Pfannkuche et al., 2009).Hmga1
and Hmga2 are highly and ubiquitously expressed during early
embryonic development (Chiappetta et al., 1996; Hirning-Folz
et al., 1998). At later stages,Hmga1 expression becomes restricted
to specific organs of all three germ layers, the ectoderm, meso-
derm and endoderm. Although Hmga1 can be detected in most
adult tissues, its expression is higher in testis, skeletal mus-
cle, and thymus (Chiappetta et al., 1996). Hmga2 expression is
mainly limited to the mesenchyme and is hardly detectable in
healthy adult tissues, except testis, skeletal muscle and adipose tis-
sues (Anand and Chada, 2000; Chieffi et al., 2002; Caron et al.,
2005). HMGA proteins in adult organs have been implicated in
maintaining and activating stem/progenitor cells in different tis-
sues (Figure 2A) (Nishino et al., 2008; Li et al., 2012). When
compared to wild-type embryonic stem (ES) cells, Hmga1−/−
ES cells form fewer and smaller embryoid bodies (EBs) and
show reduced capacity to differentiate to T lymphocytes (Caron
et al., 2005).Hmga1−/− mice suffer from hematologic malignan-
cies and cardiac hypertrophy resulting from a direct regulation
of cardiomyocyte growth (Figure 2A) (Fedele et al., 2006a). In
addition, Hmga1−/− mice show reduced insulin receptor expres-
sion leading to type 2 diabetes (Foti et al., 2005; Fedele et al.,
2006a). The interaction of HMGA1 with retinoblastoma pro-
tein (RB1, also known as pRB) and CCAAT/enhancer-binding
protein β (C/EBPβ) was shown to be important for proper regu-
lation of genes required for adipocyte differentiation (Figure 2A)
(Esposito et al., 2009). Transgenic mice carrying anHmga1b trun-
cated gene exhibit gigantism with an increased amount of the
retroperitoneal and subcutaneous white adipose tissue, possibly
due to activation of E2F transcription factor 1 (E2F1) path-
way. These mice also develop B-cell lymphomas similar to that
occurring in Hmga1−/− mice (Fedele et al., 2011).
Hmga2−/− mice show a pygmy phenotype due to reduced
expression of the insulin-like growth factor 2 mRNA binding
protein 2 (Igf2bp2) gene (Zhou et al., 1995; Brants et al., 2004;
Cleynen et al., 2007; Li et al., 2012). The Hmga2 deficient mice
also show reduced fat tissue which is linked to a function of
Hmga2 in pre-adipocyte precursor cell proliferation (Figure 2A)
(Anand and Chada, 2000). In addition, Hmga2−/− embryonic
fibroblasts have a proliferative defect. A recent study shows that
Hmga2 is extremely important for the self-renewal potential
of hematopoietic stem cells (HSCs, Figure 2A) (Copley et al.,
2013). On the other hand, transgenic mice overexpressing a
FIGURE 2 | Schematic representation of HMGA role during cell
differentiation and cancer. (A) HMGA proteins are required for proper
development and progenitor cell differentiation to adipocyte, skeletal
muscle, cardiac muscle, spermatozoids, and hematopoietic cells. They have
a dual role in neuronal differentiation, where they are required during early
neural progenitor differentiation but inhibit astrocyte differentiation at later
stages. (B) HMGA proteins are involved in cellular processes that induce
tumor formation and metastasis. Abnormal high expression of HMGA
proteins results in tumor formation and metastasis. HMGA proteins
deregulate cell cycle and thereby increase cell proliferation through either
inhibition of RB1 and induction of E2F1 (green) or activation of AP1 and
increased Cyclin A2 (Ccna2) expression (red). HMGA interaction with
TRP53 blocks its activity and results in inhibition of apoptosis (purple).
TGFB positively regulates HMGA expression (blue). HMGA interaction with
SMADs leads to epithelial mesenchymal transition (EMT).
carboxyl-terminally truncated version of Hmga2 show a giant
phenotype, are obese and develop lymphomas (Baldassarre et al.,
2001; Fedele et al., 2001). It was shown that HMGA2 is necessary
for the commitment of mouse embryonic stem cells to the skeletal
muscle (Figure 2A) (Caron et al., 2005; Li et al., 2012) and car-
diac muscle lineages (Figure 2A) (Monzen et al., 2008). HMGA
proteins are also important for the proliferation of early stage
neural precursor cells (NPCs) and for their neurogenic poten-
tial and overexpression of these genes can reprogram late stage
NPCs into cells with early stage-specific capacities suppressing
astrogenesis (Figure 2A) (Kishi et al., 2012). HMGA proteins are
required for normal sperm development; both Hmga1−/−and
Hmga2−/−mice show impaired spermatogenesis and the latter are
sterile (Figure 2A) (Chieffi et al., 2002; Liu et al., 2003).
HMGA PROTEINS AND CANCER
Hmga1 and Hmga2 are highly expressed in transformed cells in
a variety of malignant and benign tumors of different origins
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(Fusco and Fedele, 2007; Hock et al., 2007). Transformation of
a rat thyroid cell line (FRTL5) by the Kirsten murine sarcoma
virus (KiMSV) increased sharply the level of phosphorylated
HMGA proteins along with phosphorylated histone proteins
H1 and H2A, and ubiquitinated H2A. Thus, the association
of HMGA proteins with the neoplastic phenotype was demon-
strated for the first time (Giancotti et al., 1985). Subsequently,
a direct role of HMGA proteins in tumorigenesis was proven
with a loss of function of HMGA2 in normal rat thyroid cells
which prevented retrovirally induced neoplastic transformation
(Berlingieri et al., 1995). More direct evidence of the tumorigenic
potential of HMGA proteins came when normal cells in culture
overexpressing these proteins underwent oncogenic transforma-
tion (Wood et al., 2000). For example, the human breast epithelial
cell line MCF7 acquired the ability to form both primary and
metastatic tumors in nude mice after overexpression of HMGA1
(Reeves et al., 2001). In general, there are accumulating reports
supporting that HMGA proteins are required and sufficient for
neoplastic transformation (Di Cello et al., 2008; Winslow et al.,
2011; Morishita et al., 2013; Sun et al., 2013).
HMGA proteins contribute to tumor formation by inhibit-
ing the apoptotic function of the transformation related protein
53 (TRP53, also known as P53) (Figure 2B). Two mechanisms
have been reported for this inhibition. HMGA1 directly binds
to and inactivates TRP53 thereby modulating the transcription
of its target genes Cdkn1a (cyclin-dependent kinase inhibitor
1A, also known as p21), Bcl2 (B cell leukemia/lymphoma 2)
and Bax (Bcl2-associated X protein and cyclin-dependent kinase
inhibitor 1A), while enabling the active transcription of the
TRP53 inhibitorMdm2 (Frasca et al., 2006; Pierantoni et al., 2006;
Esposito et al., 2010, 2012). The second mechanism is indirect
and involves translocation of HIPK2 (homeodomain-interacting
protein kinase 2) to the cytoplasm. HIPK2 phosphorylates p53 at
S46 in the nucleus to induce apoptosis after non-repairable DNA
damage has taken place (Pierantoni et al., 2007). The cytoplas-
mic translocation of HIPK2 abolishes the apoptotic function of
TRP53.
Another mechanism by which HMGA proteins exert their
tumorigenic activity is by interfering with cell cycle (Figure 2B).
RB1 is one of the main cell cycle regulator proteins and keeps
the E2F1 inactive in a complex with HDAC1 resulting in tran-
scriptional repression. HMGA2 is able to bind RB1 and displace
HDAC1 from the complex. Subsequent recruitment of the his-
tone acetyl transferase EP300 (E1A binding protein p300, also
known as P300) to the complex results in acetylation of DNA
associated histones. E2F1 leads to activation of the protein com-
plex and target gene transcription (Fedele et al., 2006b). The
activation of E2F1 mediated by HMGA2 was shown to induce
pituitary adenomas. Interestingly, a recent study has shown that
human HMGA1 promoter is target of E2F1 and the deregulated
RB1/E2F1 pathway might contribute to deregulation of HMGA1
in cancer (Figure 2B) (Massimi et al., 2013).
HMGA proteins interfere with cell cycle also by regulating
the expression of Cyclin A2 (Ccna2) gene through the E2F1
(Schulze et al., 1995) and AP1 complexes (Casalino et al., 2007)
(Figure 2B). AP1 complex can be composed of three Jun pro-
teins (JUN, JUNB and JUND) and four Fos proteins (FOS, FOSB,
FRA1, and FRA2). It was reported that HMGA protein levels
increased in RAS-transformed rat thyroid cells, which in return
increased the transcription of Junb and Fra1 (Vallone et al., 1997).
In these transformed cells, AP1 complex is mainly composed of
JUNB-FRA1 heterodimers, and this compositional change leads
to increased transcriptional activity of the AP1 complex explain-
ing the high levels of Ccna2.
During epithelial-mesenchymal transition (EMT), polarized
epithelial cells undergo several biochemical processes that result
in a transition to a mesenchymal cell phenotype (Thiery and
Sleeman, 2006; Kalluri and Weinberg, 2009). These processes
include altered cell-cell and cell-extracellular matrix (ECM) inter-
actions and reorganization of the cytoskeleton, both leading to
an increased ability of the cells to migrate. Although EMT occurs
during normal embryonic development, it is also a key process
during tumorigenesis and metastasis. The transforming growth
factor beta (TGFB) signaling pathway is able to induce EMT
and has been involved in cancer initiation and metastasis. TGFB
increases the expression of Hmga2 by SMAD3 mediated inhi-
bition of let-7, a microRNA that targets Hmga2 transcript (Lee
and Dutta, 2007). HMGA2 was found to be required for TGFB
signaling and to interact with several SMAD proteins which are
mediators of the TGFB signaling (Figure 2B) (Thuault et al.,
2006, 2008; Watanabe et al., 2009; Wu et al., 2011; Zha et al.,
2012). Moreover, HMGA and SMADs have been shown to coreg-
ulate the expression of SNAIL1 (Protein snail homolog 1), which
is the master effector for the induction of EMT in mammary
epithelial cells (Thuault et al., 2008). Taking all these together, it
will be of interest from the therapeutic point of view to inves-
tigate whether HMGA proteins are required for TGFB induced
EMT during tumorigenesis and metastasis. Indeed, the multiple
roles of TGFB signaling in tumor progression have promoted the
development of therapeutic agents based on the inhibition of this
signaling pathway (Golestaneh and Mishra, 2005; Ikushima et al.,
2009). Interestingly, it has been recently shown that HMGA2
increased the expression of the TGFB type II receptor thereby
enhancing TGFB signaling in epithelial carcinomas (Morishita
et al., 2013).
LIN-28, a developmentally regulated RNA binding protein
which is expressed at high levels in undifferentiated ES cells, has
been shown to inhibit let-7 microRNA biogenesis (Thornton and
Gregory, 2012).The balance between LIN-28 and let-7 affects the
expression of Hmga2 and therefore is important for ES cell self-
renewal and differentiation (Li et al., 2012; Copley et al., 2013)
and maintenance of an undifferentiated state in cancer cells (Shell
et al., 2007). Moreover, a recent study has shown that Hmga2
could promote cancer progression by acting as a competing endo-
geneous RNA (ceRNA) for let-7, adding another complexity to
the mechanism by which Hmga2 can contribute to tumorigene-
sis (Kumar et al., 2013). LIN-28/let-7 axis also regulates glucose
uptake (Zhu et al., 2011) and has the ability to reprogram cells
toward glycolytic metabolism (Thornton and Gregory, 2012).
This different metabolism, which is a hallmark of cancer, is
known as the “Warburg Effect.”
Chromosomal rearrangements have also been reported in a
variety of common benign tumors. Among these, rearrangements
of the HMGA2 gene at 12q15 seem to be the most common
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rearrangements in human tumors of mesenchymal origin. The
role of HMGA translocations in the formation of various human
tumors has been previously reviewed (Fusco and Fedele, 2007;Wu
and Wei, 2013).
CONCLUSIONS AND PERSPECTIVE
High mobility group (HMG) proteins are the most abundant
non-histone chromatin associated proteins. Members of the
HMGA subfamily contain a unique DNA-binding domain, the
AT-hook, which can bind AT-rich DNA sequences with high
affinity. HMGA proteins act as architectural transcription fac-
tors, which means that although they do not possess intrinsic
transcriptional activity, they have the ability to modulate tran-
scription of their target genes by altering the chromatin struc-
ture in different ways: displacement of histone H1 leading to
chromatin decompaction, high-order chromatin rearrangements
resulting in DNA looping that brings enhancers and promoter
in close proximity, promoting assembly of regulatory nucleopro-
tein complexes, such as enhanceosomes and transcription initia-
tion complexes, facilitating nucleosome remodeling and thereby
accessibility of DNA to transcription factors and recruiting tran-
scription factors to specific promoters.
HMGA proteins undergo several post-translational modifica-
tions, such as phosphorylation (Nissen et al., 1991; Wang et al.,
1995; Schwanbeck et al., 2000; Pierantoni et al., 2001; Di Agostino
et al., 2004; Zhang and Wang, 2007), methylation (Sgarra et al.,
2003; Edberg et al., 2004, 2005; Sgarra et al., 2006), acetyla-
tion (Munshi et al., 1998, 2001; Zhang et al., 2007), sumoylation
(Cao et al., 2008) and ribosylation (Elton and Reeves, 1986).
Here, we have discussed only the role of phosphorylation of
HMGA proteins mediated by the kinases DNA-PK, ATM and ATR
at the SQ sites during transcriptional regulation. The biologi-
cal relevance of the other modifications is not well understood
and requires more attention. It would be interesting to analyze
also the other post-translational modifications to understand the
molecular mechanisms underlying their role in fine-tuning the
interaction of HMGA proteins with other transcription factors,
with the chromatin and with the DNA.
HMGA proteins are present at high levels in various undiffer-
entiated tissues and several studies confirmed their central role
during normal embryonic development. They contribute to the
plasticity of ES cells by maintaining an open chromatin state
evicting linker histone H1 which facilitates formation of nucleo-
protein structures at specific promoters (Pfannkuche et al., 2009;
Kishi et al., 2012). Hence, it is not surprising that HMGA protein
levels are developmentally regulated; they are strongly reduced or
almost absent in adult organs, where they have been implicated
in maintaining and activating stem/progenitor cells in different
tissues. Regeneration of adult organs during normal homeo-
static turnover or after injury requires a proper balance between
self-renewal and differentiation of tissue-specific progenitor cells.
On the other hand, re-expression of both Hmga1 and Hmga2
at high levels in the adult stage is seen in a variety of malig-
nant and benign tumors, which might be in part due to their
role in transcription activation of certain cell proliferation genes.
Characterization of the role of HMGA proteins in the regulatory
mechanisms controlling the proper balance between expansion
and differentiation of progenitor cells will have a profound impact
on our understanding and treatment of diseases originated from
improper regulation of HMGA proteins, such as cancer, diabetes
and idiopathic pulmonary fibrosis (Pandit et al., 2010).
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